Date: 2013-10-02
Type of information: Licensing agreement
Compound: EB66® cell line
Company: Valneva (France) International AIDS Vaccine Initiative (IAVI)
Therapeutic area: Infectious diseases
Type agreement: licensing
Action mechanism:
Disease: HIV-Aids
Details: * On October 2, 2013, Valneva, a European biotechnology company focused on vaccines and antibodies research and development, has announced that it has licensed the use of its EB66® cell line to the International AIDS Vaccine Initiative (IAVI) for the evaluation and development of a preventive HIV vaccine candidate in clinical trials. The agreement is a landmark in Valneva’s history, as it is the first time the company has given dual rights to a non-profit organization to perform both research and clinical studies using its technology. Valneva has historically separated the two functions in its licensing agreements.
The license allows IAVI to use Valvena’s EB66© cell line through Phase II study of a vector-based vaccine candidate derived from a modified version of the canine distemper virus (CDV). The agreement was signed following a successful proof-of-concept demonstration by Valneva for the EB66® cell line technology. The CDV vector is being developed with support from the United States Agency for International Development (USAID) and a Collaboration for AIDS Vaccine Discovery grant from the Bill and Melinda Gates Foundation.
Financial terms of this non-exclusive agreement were not disclosed. If successful, the program could lead to a commercial license agreement.
Financial terms: Financial terms of this non-exclusive agreement were not disclosed.
Latest news:
